Could a common heartburn drug ease COVID-19 symptoms?

NCT ID NCT04724720

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether famotidine, the active ingredient in Pepcid, can help relieve COVID-19 symptoms in adults who are not sick enough to be hospitalized. Participants receive either famotidine or a placebo, along with standard care, and report their symptoms remotely. The study aims to see if famotidine speeds up recovery and reduces symptom severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

famotidine (Pepcid)

What this could lead to

If effective, famotidine could offer a widely available, low-cost option to ease COVID-19 symptoms at home.

What could go wrong

This is a small Phase 2 trial, so results may not be conclusive. Famotidine is not a proven COVID-19 treatment, and any benefit may be minimal or absent.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwell Health

    Lake Success, New York, 11042, United States